CytomX Therapeutics Inc (NASDAQ:CTMX)
| 1.39 Delayed Data As of Nov 30 |  +0.06 / +4.51%Today’s Change | 1.04 Today|||52-Week Range 3.02 | -13.13% Year-to-Date |
Five Year Financial Summary
| All Currency in US Dollars | 4 Year Trend | |||||
|---|---|---|---|---|---|---|
2015 | 2016 | 2017 | 2018 | |||
| Revenue and Income | Net Revenues | 7.7M | 15.0M | 71.6M | 59.5M | |
| Depreciation And Amortization | 1.2M | 1.7M | 1.6M | 1.9M | ||
| Operating Expenses | Gross Income | -- | -- | -- | -- | -- |
| General Expenses | 39.7M | 72.9M | 116.2M | 135.5M | ||
| Research And Development | 28.4M | 54.8M | 92.3M | 103.9M | ||
| Total Operating Expenses | 40.9M | 74.6M | 117.9M | 137.4M | ||
| Non-Operating Expenses | Operating Income | -33.2M | -59.6M | -46.3M | -77.9M | |
| Extraordinary Charge | -1.7M | 0.00 | 0.00 | 0.00 | ||
| Interest Expense On Debt | 1.7M | 1.7M | 0.00 | 0.00 | ||
| Other Expenses | -28.0K | -69.0K | -27.0K | -68.0K | ||
| Income Taxes, Minority Interest and Extra Items | Pre-Tax Income | -35.4M | -58.9M | -43.6M | -70.3M | |
| Income Taxes | -10.0K | -19.0K | -513.0K | -14.3M | ||
| Preferred Dividend | -6.7M | 0.00 | 0.00 | 0.00 | ||
| Net Income | -35.4M | -58.9M | -43.1M | -84.6M | ||
| Shares To Calculate EPS | Shares To Calculate EPS | 8.6M | 36.2M | 37.2M | 41.7M | |
| Shares To Calculate EPS Diluted | 8.6M | 36.2M | 37.2M | 41.7M | ||
| Earnings Per Share | EPS | -$4.90 | -$1.63 | -$1.16 | -$2.03 | |
| EPS Diluted | -$4.90 | -$1.63 | -$1.16 | -$2.03 | ||
